Bevacizumab maintenance in metastatic colorectal cancer: How long?

作     者：Alfonso De Stefano Roberto Moretto Chiara Alessandra Cella Francesco Jacopo Romano Lucia Raimondo Giovanni Fiore Francesca Di Pietro Stefano Pepe Sabino De Placido Chiara Carlomagno 

作者机构：Department of Clinical Medicine and SurgerySchool of Medicine University of Naples "Federico II" 80131 Napoli Italy Department of Medicine School of Medicin and Pharmacology University of Salerno 84081 Baronissi (SA)Italy 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2014年第2卷第11期

页      面：717-723页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Metastatic colorectal cancer Bevacizumab Maintenance 

摘      要：The management of patients with non-progressive metastatic colorectal cancer after six months of treatment has not yet been codified. The most relevant concerns are the effectiveness of maintenance versus discontinuation, and the tolerability of prolonged treatment. Here we report the case of a 72-year-old man affected by colorectal cancer with lung metastases who achieved a complete response after receiving capecitabine, oxaliplatin and bevacizumab for six months, and bevacizumab alone for six months. Bevacizumab was continued as maintenance regimen for more than three years. It was discontinued because of an arthroplasty. Fifty-eight months after beginning first-line treatment, the patientremains free from relapse. Adverse effects were minimal and easily controlled.